(TheNewswire)
Vancouver, British Columbia – November 01, 2021 –Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the “ Corporation ” or“ Blackhawk ”), is pleased to announce that MindBio Therapeutics PtyLtd (“ MindBio ”) is working to expand its microdosing clinical trials. MindBio is a multi-disciplinary company pioneering new treatmentsfor mental health conditions using psychedelic medicines, technologyassisted mental health interventions and psychedelic assistedpsychotherapies.
MindBio is currently undertaking a world’s firstclinical trial of its kind. In its phase 1 clinical trial microdosingLSD (Lysergic Acid Diethylamide), MindBio is microdosing LSD to 80healthy participants who take the drug at home in the same way thatthey would take any other medication. MindBio will lead phase 2clinical trials microdosing LSD to patients with major depressivedisorder and in patients with late-stage cancer - with those trialsset to begin in mid-2022.
Pre-clinical research has demonstrated that psychedelicsubstances, including LSD, psilocybin, ayahuasca and DMT, affectneuroplasticity after acute and chronic administration. The datagenerated from in-vitro studies conducted by the BeckleyFoundation 1 demonstrated neuroplasticity by the presence of Brain DerivedNeurotropic Factor (BDNF) in blood plasma. Studies conducted at theUniversity of California, Davis 2 have also shownthat microdosing psychedelics such as LSD and psilocybin promoteincreased neurite growth, spine density and synaptogenesis.
MindBio is currently assessing natural psilocybin andpotential analogs as a candidate for phase 1 microdosing clinicaltrials. The company can scale microdosing clinical trials to othersubstances quickly and cost effectively. MindBio is seeking adviceon designing the clinical trial protocols given the potential forpsilocybin to treat a number of mental health conditions such as majordepressive disorder, PTSD and anxiety.
In addition, Blackhawk’s CEO, Frederick Pels, will becontributing to the psychedelics microdosing discussions at theupcoming Wonderland convention in Miami, where MindBio is a GoldSponsor. The event is being promoted by conference organiser Microdose as “the biggest psychedelics business event,ever”.
-
1. https://www.beckleyfoundation.org/2018/06/13/psychedelics-promote-neural-plasticity/
-
2. https://www.cell.com/cell-reports/fulltext/S2211-1247(18)30755-1
About Blackhawk Growth
Blackhawk is an investment holding company looking tocreate substantial value for its shareholders through the acquisitionand development of high growth companies. It has focused itsinvestments in the health, cannabis and cannabidiol industries in bothCanada and the United States. Its portfolio of companies includes SacPharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, andMindBio Therapeutics. Blackhawk continues tobring its investments to cash flow and is growing at an exceedingpace.
The Company diligently posts updates through videosfrom the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A
Please join the conversation on our Blackhawk groupsupporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com .
For further information please contact:
Frederick Pels, Chief ExecutiveOfficer
(403)-991-7737
fred@ blackhawkgrowth.com
Cautionary NoteRegarding Forward-Looking Statement
All statements in this pressrelease, other than statements of historical fact, are “forward-looking information”with respect to the Company within the meaning of applicablesecurities laws, including with respect to transaction and futureoperations of MindBio Therapeutics Pty Ltd. The Company providesforward-looking statements for the purpose of conveying informationabout current expectations and plans relating to the future andreaders are cautioned that such statements may not be appropriate forother purposes. By its nature, this information is subject to inherentrisks and uncertainties that may be general or specific and which giverise to the possibility that expectations, forecasts, predictions,projections or conclusions will not prove to be accurate, thatassumptions may not be correct and that objectives, strategic goalsand priorities will not be achieved. These risks and uncertaintiesinclude but are not limited those identified and reported in theCompany’s public filings under the Company’s SEDAR profile atwww.sedar.com. Although the Company has attempted to identifyimportant factors that could cause actual actions, events or resultsto differ materially from those described in forward-lookinginformation, there may be other factors that cause actions, events orresults not to be as anticipated, estimated or intended. There can beno assurance that such information will prove to be accurate as actualresults and future events could differ materially from thoseanticipated in such statements. The Company disclaims any intention orobligation to update or revise any forward-looking information,whether as a result of new information, future events or otherwiseunless required by law.
Copyright (c) 2021 TheNewswire - All rights reserved.